查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081917

單株抗體療法市場：2026-2032年全球市場預測（按抗體類型、適應症、分子標靶、生產技術、給藥途徑、療法、最終用戶和分銷管道分類）

Monoclonal Antibody Therapeutics Market by Antibody Type, Indication, Molecular Target, Production Technology, Route Of Administration, Therapy Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，單株抗體療法市場將成長至 6,725 億美元，複合年成長率為 13.71%。

主要市場統計數據
基準年 2025 2734.5億美元
預計年份：2026年 3103.9億美元
預測年份 2032 6725億美元
複合年成長率 (%) 13.71%

單株抗體療法是臨床驗證最檢驗、商業性價值最高的生物製藥類別之一，已在腫瘤學、自體免疫疾病、發炎性疾病、感染疾病預防、眼科、神經病學和移植醫學等領域廣泛應用。其策略優勢源自於數十年來與監管機構的合作經驗、不斷擴大的適應症範圍，以及抗體與疾病相關標靶高特異性結合的成熟能力。

這一成長主要得益於從第一代鼠源抗體和嵌合體抗體轉變為人源化抗體、全人源抗體、雙特異性抗體、抗體藥物複合體（ADC）、Fc修飾抗體和皮下製劑的轉變。生物相似藥的競爭、支付方對價值的需求，以及對生物製藥生產能力、低溫運輸物流、藥物安全監測和真實世界數據（REW）產生的持續投資，也推動了該行業對這些藥物的採用。

單株抗體領域的變革性變化

單株抗體療法領域正從逐一產品創新的模式轉向平台主導的生態系統。雖然腫瘤學仍然是主要領域，但基於抗體的療法的臨床應用範圍正在擴大，涵蓋免疫介導疾病、阿茲海默症、呼吸道融合細胞病毒（RSV）效用、偏頭痛、高膽固醇症和罕見疾病。

人工智慧的累積影響

人工智慧 (AI) 對單株抗體療法的各個階段都產生了累積的影響，從藥物發現和開發到生產和商業化。 AI 驅動的蛋白質建模、抗體序列最佳化、可行性篩檢和表位預測，使研究人員能夠在進行成本高昂的實驗室檢驗之前，優先篩選出具有強結合特性、低聚集風險和更佳生產性能的候選藥物。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

亞太地區正因生物製藥生產的擴張、癌症和自體免疫疾病診斷率的上升，以及各國鼓勵生物相似藥引進和本土創新的政策，而日益成為戰略要地。中國、印度、日本、韓國、澳洲和東協等市場在臨床開發、契約製造和商業性擴張等領域的影響力與日俱增，這得益於不斷擴大的臨床試驗活動以及監管標準與國際標準的日益接軌。

來自主要區域組織的見解：東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約

隨著各國政府擴大全民健康覆蓋（UHC）、癌症治療服務和生物製藥採購，東協市場對單株抗體療法的重要性日益凸顯。同時，法規核准流程的簡化和區域合作的加強也提高了藥物的可及性。海灣合作理事會（GCC）成員國優先發展專科醫療、醫療體系現代化、癌症治療能力和本土製藥能力，這為高階生物製藥、生物相似藥和醫院靜脈輸液服務創造了新的機會。

對主要單株抗體市場關鍵國家的洞察

美國憑藉其健全的FDA核准體系、專業的藥房網路、完善的醫保支付管理、高密度的臨床試驗以及利用先進生物標記的治療路徑，在全球單株抗體商業化領域處於領先地位。加拿大則著重於醫療技術評估和省級醫保報銷機制，而墨西哥則透過公共和私營醫療管道擴大專科藥物的可近性。巴西仍然是拉丁美洲最重要的生物製藥市場，這得益於對癌症治療的需求、生物相似藥的引入以及在地化生產的努力。

為行業領導者提供的實用建議

在競爭激烈的適應症領域，產業供應商應優先開發具有明確臨床價值的差異化抗體平台，而非增量產品。透過在研發早期階段協調標靶選擇、生物標記策略、病患細分、伴隨診斷規劃和衛生經濟學證據，可以取得更佳的療效。

調查方法

本執行摘要採用系統性的二手研究途徑編寫，依據公開的監管、臨床、科學和醫療政策資訊來源。主要資訊來源包括藥物核准資料庫、臨床試驗註冊資訊、同儕審查文獻、衛生監管機構公告、報銷框架、藥物安全監測資源、生物相似藥政策文件以及廣受認可的行業出版物。

結論

隨著醫療系統尋求針對高疾病負擔疾病的標靶實證療法，單株抗體療法預計將繼續保持其重要的戰略地位。該領域的下一階段將以差異化療法、生物相似藥帶來的更廣泛的可及性、區域製造地的擴張以及診斷、資料科學、藥物安全監測和真實世界數據（RWE）的更緊密整合為特徵。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：單株抗體治療市場：依抗體類型分類

  • 嵌合體體
  • 完全人形
  • 人性化
  • 小鼠來源

第8章：單株抗體療法市場：依適應症分類

  • 自體免疫疾病
    • 發炎性腸道疾病
    • 多發性硬化症
    • 銀屑病
    • 類風濕性關節炎
  • 心血管疾病
  • 感染疾病
    • 冠狀病毒感染疾病（COVID-19）
    • HIV
    • 呼吸道融合細胞病毒
  • 神經病變
    • 阿茲海默症
    • 多發性硬化症
  • 腫瘤學
    • 骨髓惡性腫瘤
      • 白血病
      • 多發性骨髓瘤
      • 非何傑金氏淋巴瘤
    • 固體癌

第9章：單株抗體治療市場：依分子標靶

  • CD20
  • EGFR
  • HER2
  • 腫瘤壞死因子-α

第10章：單株抗體治療市場：依生產技術分類

  • 融合瘤
  • 重組DNA
  • 基因改造動物

第11章：單株抗體治療市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 皮下

第12章：單株抗體療法市場：依療法類型分類

  • 聯合治療
  • 單藥治療

第13章：單株抗體治療市場：依最終用戶分類

  • 診所
  • 診斷檢查室
  • 醫院
  • 專業醫療中心

第14章：單株抗體治療市場：依通路分類

  • 物理藥房
    • 醫院藥房
    • 零售藥房
    • 專科藥房
  • 網路藥房

第15章：單株抗體療法市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章：單株抗體治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 單株抗體療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Corvidia Therapeutics Inc. by Novo Nordisk A/S
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GenScript
  • Gilead Sciences, Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck Sharp & Dohme Corp.,
  • Novartis International AG
  • Pfizer Inc
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4316E4E89474

The Monoclonal Antibody Therapeutics Market is projected to grow by USD 672.50 billion at a CAGR of 13.71% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 273.45 billion
Estimated Year [2026] USD 310.39 billion
Forecast Year [2032] USD 672.50 billion
CAGR (%) 13.71%

Monoclonal antibody therapeutics remain one of the most clinically validated and commercially important classes in biologic medicines, with established use across oncology, autoimmune disorders, inflammatory diseases, infectious disease prevention, ophthalmology, neurology, and transplant medicine. Their strategic strength is supported by decades of regulatory experience, expanding indication coverage, and the proven ability of antibodies to bind disease-relevant targets with high specificity.

Growth is being shaped by the shift from first-generation murine and chimeric antibodies to humanized, fully human, bispecific, antibody-drug conjugate, Fc-engineered, and subcutaneous formulations. Industry adoption is also being reinforced by biosimilar competition, payer demand for value, and continued investment in biologics manufacturing capacity, cold-chain logistics, pharmacovigilance, and real-world evidence generation.

Transformative Shifts in the Monoclonal Antibody Landscape

The monoclonal antibody therapeutics landscape is transforming from a product-by-product innovation cycle into a platform-led ecosystem. Oncology remains a leading field, but immune-mediated diseases, Alzheimer's disease, respiratory syncytial virus prevention, migraine, hypercholesterolemia, and rare diseases demonstrate the broadening clinical utility of antibody-based therapies.

Competitive differentiation is increasingly driven by mechanism of action, route of administration, dosing interval, biomarker strategy, safety profile, and manufacturability. Subcutaneous delivery, longer half-life designs, dual-targeting antibodies, and antibody-drug conjugates are improving patient convenience and clinical outcomes, while biosimilars are reshaping pricing and access in mature therapeutic areas such as oncology and immunology.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across discovery, development, manufacturing, and commercialization of monoclonal antibody therapeutics. AI-enabled protein modeling, antibody sequence optimization, developability screening, and epitope prediction help researchers prioritize candidates with stronger binding profiles, lower aggregation risk, and more favorable manufacturability attributes before costly wet-lab validation.

In clinical development, machine learning supports trial site selection, patient stratification, biomarker discovery, adverse event signal detection, and real-world evidence analysis. In manufacturing, AI-assisted process analytics, predictive maintenance, and digital twins are improving batch consistency, reducing deviations, and supporting quality-by-design practices. The greatest value is emerging where AI is paired with validated biological data, rigorous regulatory documentation, and human scientific oversight.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

Asia-Pacific is gaining strategic importance through expanding biologics manufacturing, rising cancer and autoimmune disease diagnosis, and national policies that encourage biosimilar uptake and domestic innovation. China, India, Japan, South Korea, Australia, and ASEAN markets are becoming more influential across clinical development, contract manufacturing, and commercial expansion, supported by growing clinical trial activity and improving regulatory alignment with international standards.

North America remains a core innovation and commercialization hub, led by the United States with deep venture funding, advanced academic research, FDA regulatory experience, established specialty pharmacy infrastructure, and broad biologics adoption. Canada contributes through clinical research networks and public reimbursement frameworks that increasingly assess cost effectiveness. Latin America is advancing through expanding oncology access, biologics procurement reform, and biosimilar adoption, with Brazil and Mexico serving as central markets for regional commercialization.

Europe benefits from the European Medicines Agency's mature biosimilar pathway, national health technology assessment systems, and strong pharmaceutical manufacturing clusters, making the region highly influential in clinical evidence standards and post-authorization safety monitoring. The Middle East is investing in specialty care infrastructure, oncology centers, and biologics procurement modernization, particularly in GCC countries. Africa remains earlier in adoption, but demand is rising as cancer care capacity, diagnostic access, cold-chain systems, and public-private healthcare investment expand.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7 & NATO

ASEAN markets are increasingly relevant for monoclonal antibody therapeutics because governments are expanding universal health coverage, oncology services, and biologics procurement, while regulatory reliance pathways and regional cooperation are helping accelerate access. GCC countries are prioritizing specialty care, health system modernization, cancer treatment capacity, and local pharmaceutical capability, creating opportunities for premium biologics, biosimilars, and hospital-based infusion services.

The European Union remains a benchmark for biosimilar policy, pharmacovigilance, centralized regulatory review, and health technology assessment, supporting competition while maintaining strict quality standards. BRICS countries represent a high-priority access frontier due to large patient populations, rising biologics manufacturing capability, expanding clinical trial activity, and government interest in reducing dependence on imported high-cost medicines.

G7 markets continue to shape global standards in clinical evidence, pricing, reimbursement, intellectual property, pharmacovigilance, and biologics quality. NATO-aligned countries, many of which overlap with high-income European and North American markets, are also strengthening supply resilience, domestic biomanufacturing, medicine security, and critical healthcare preparedness after pandemic-era supply disruptions.

Key Country Insights Across Major Monoclonal Antibody Markets

The United States leads global monoclonal antibody commercialization through strong FDA approvals, specialty pharmacy networks, payer management, high clinical trial density, and advanced biomarker-enabled care pathways. Canada emphasizes health technology assessment and provincial reimbursement, while Mexico is expanding specialty medicine access through public and private healthcare channels. Brazil remains Latin America's most significant biologics market, supported by oncology demand, biosimilar adoption, and local production initiatives.

The United Kingdom, Germany, France, Italy, and Spain are major European markets where reimbursement decisions, biosimilar tendering, hospital procurement, and clinical guideline adoption determine uptake. Germany's strong biopharmaceutical base and early market access pathway are influential, while France, Italy, and Spain leverage national procurement and hospital systems to manage biologics spending. Russia has supported domestic biologics production, though market access is affected by geopolitical and supply-chain constraints.

China has become a major force in antibody R&D, clinical trials, biosimilars, and domestic commercialization, supported by regulatory reforms and expanding oncology care. India is a leading biosimilar and biomanufacturing participant with cost-efficient development capabilities and increasing demand for affordable biologics. Japan's market is driven by aging demographics, regulatory quality, and high-value specialty care, while Australia supports advanced clinical research and reimbursement through evidence-based assessment. South Korea is globally recognized for biosimilar manufacturing, contract development, and biologics export strength.

Actionable Recommendations for Industry Leaders

Industry vendors should prioritize differentiated antibody platforms with clear clinical value over incremental products in crowded indications. Stronger outcomes can be achieved by aligning target selection, biomarker strategy, patient segmentation, companion diagnostic planning, and health economic evidence early in development.

Organizations should invest in flexible biomanufacturing, high-yield cell line development, continuous processing, analytical characterization, and resilient supply chains to manage demand volatility and quality expectations. Commercial teams should prepare for biosimilar competition through lifecycle management, subcutaneous formulations, patient support services, physician education, and evidence packages that demonstrate real-world effectiveness, safety, and budget impact.

AI adoption should be governed by transparent validation, data lineage, cybersecurity safeguards, model monitoring, and regulatory-ready documentation. Partnerships with academic centers, contract development and manufacturing organizations, diagnostic specialists, healthcare providers, and regional distributors can accelerate global reach while reducing operational, regulatory, and access-related risk.

Research Methodology

This executive summary is developed using a structured secondary research approach anchored in publicly available regulatory, clinical, scientific, and healthcare policy sources. Core inputs include drug approval databases, clinical trial registries, peer-reviewed literature, health authority communications, reimbursement frameworks, pharmacovigilance resources, biosimilar policy documents, and recognized industry publications.

Insights are triangulated across therapeutic area trends, regional policy developments, biologics manufacturing capacity, biosimilar adoption, clinical trial activity, regulatory pathways, and technology shifts such as AI-enabled discovery and process analytics. The methodology emphasizes evidence consistency, source credibility, relevance to monoclonal antibody therapeutics, and exclusion of unsupported claims, market sizing, market share, and forecasting statements.

Conclusion

Monoclonal antibody therapeutics are positioned for continued strategic importance as healthcare systems seek targeted, evidence-based treatments for high-burden diseases. The sector's next phase will be defined by differentiated modalities, biosimilar-driven access, regional manufacturing expansion, and stronger integration of diagnostics, data science, pharmacovigilance, and real-world evidence.

Organizations that combine scientific innovation with scalable manufacturing, payer-aligned value evidence, robust quality systems, and disciplined AI implementation will be best placed to compete. As global demand expands across oncology, immunology, infectious disease prevention, neurology, and rare diseases, leadership will depend on delivering clinically meaningful outcomes while improving affordability, reliability, and patient access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Monoclonal Antibody Therapeutics Market, by Antibody Type

  • 7.1. Chimeric
  • 7.2. Fully Human
  • 7.3. Humanized
  • 7.4. Murine

8. Monoclonal Antibody Therapeutics Market, by Indication

  • 8.1. Autoimmune Disorders
    • 8.1.1. Inflammatory Bowel Disease
    • 8.1.2. Multiple Sclerosis
    • 8.1.3. Psoriasis
    • 8.1.4. Rheumatoid Arthritis
  • 8.2. Cardiovascular Conditions
  • 8.3. Infectious Diseases
    • 8.3.1. Covid-19
    • 8.3.2. HIV
    • 8.3.3. Respiratory Syncytial Virus
  • 8.4. Neurological Disorders
    • 8.4.1. Alzheimer's Disease
    • 8.4.2. Multiple Sclerosis
  • 8.5. Oncology
    • 8.5.1. Hematological Malignancies
      • 8.5.1.1. Leukemia
      • 8.5.1.2. Multiple Myeloma
      • 8.5.1.3. Non-Hodgkin Lymphoma
    • 8.5.2. Solid Tumors

9. Monoclonal Antibody Therapeutics Market, by Molecular Target

  • 9.1. CD20
  • 9.2. EGFR
  • 9.3. HER2
  • 9.4. TNF Alpha

10. Monoclonal Antibody Therapeutics Market, by Production Technology

  • 10.1. Hybridoma
  • 10.2. Recombinant DNA
  • 10.3. Transgenic Animal

11. Monoclonal Antibody Therapeutics Market, by Route Of Administration

  • 11.1. Intramuscular
  • 11.2. Intravenous
  • 11.3. Subcutaneous

12. Monoclonal Antibody Therapeutics Market, by Therapy Type

  • 12.1. Combination Therapy
  • 12.2. Monotherapy

13. Monoclonal Antibody Therapeutics Market, by End User

  • 13.1. Clinics
  • 13.2. Diagnostic Laboratories
  • 13.3. Hospitals
  • 13.4. Specialty Centers

14. Monoclonal Antibody Therapeutics Market, by Distribution Channel

  • 14.1. Offline Pharmacy
    • 14.1.1. Hospital Pharmacy
    • 14.1.2. Retail Pharmacy
    • 14.1.3. Specialty Pharmacy
  • 14.2. Online Pharmacy

15. Monoclonal Antibody Therapeutics Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Monoclonal Antibody Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Monoclonal Antibody Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. AbbVie Inc.
  • 19.2. Amgen Inc.
  • 19.3. Astellas Pharma Inc.
  • 19.4. Bayer AG
  • 19.5. Biogen Inc.
  • 19.6. Bristol-Myers Squibb Company
  • 19.7. Corvidia Therapeutics Inc. by Novo Nordisk A/S
  • 19.8. Eli Lilly and Company
  • 19.9. F. Hoffmann-La Roche Ltd
  • 19.10. GenScript
  • 19.11. Gilead Sciences, Inc
  • 19.12. GlaxoSmithKline Plc
  • 19.13. Johnson & Johnson
  • 19.14. Merck Sharp & Dohme Corp.,
  • 19.15. Novartis International AG
  • 19.16. Pfizer Inc
  • 19.17. Regeneron Pharmaceuticals, Inc.
  • 19.18. Sanofi S.A
  • 19.19. Takeda Pharmaceutical Company Limited
  • 19.20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHIMERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHIMERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHIMERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FULLY HUMAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FULLY HUMAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FULLY HUMAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMANIZED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMANIZED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMANIZED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MURINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MURINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MURINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOVASCULAR CONDITIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOVASCULAR CONDITIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR CONDITIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COVID-19 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COVID-19 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COVID-19 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HIV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HIV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CD20 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CD20 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CD20 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EGFR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EGFR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EGFR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HER2 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HER2 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HER2 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TNF ALPHA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TNF ALPHA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TNF ALPHA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HYBRIDOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HYBRIDOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HYBRIDOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RECOMBINANT DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RECOMBINANT DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RECOMBINANT DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRANSGENIC ANIMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TRANSGENIC ANIMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRANSGENIC ANIMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL SPECIALTY PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL SPECIALTY PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL SPECIALTY PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 249. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 257. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 258. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. GCC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 294. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 297. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 299. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 302. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 303. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. G7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 309. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 312. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 313. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 314. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 315. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 317. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 318. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 323. NATO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 324. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MAR